Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy ?
Source: Businesswire
Financial Performance: Novo Integrated Sciences reported a revenue increase of 6% to $13.29 million for the fiscal year ending August 31, 2024, but also experienced a net loss of $16.17 million, up 22% from the previous year, primarily due to impairment of assets and increased operating costs.
Business Strategy: The company is focused on expanding its healthcare services and product offerings through a decentralized healthcare model that integrates technology and service networks, aiming to improve patient access and reduce healthcare costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
